Fangda assists Brattea in completing its high-value series-D financing_News_About

Fangda assists Brattea in completing its high-value series-D financing

2024 / 04 / 24

Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.

Previous：Fangda represents Mindray in its strategic acquisition of the controlling shareholding right of APT, a listed company on the STAR Market Board

Next：Fangda assisted Voneseals in completing a material asset restructuring transaction through equity acquisition of Shanghai Garnor

2026 / 05 / 29

Fangda Advises WuXi AppTec on the Issuance of RMB 6.78 Billion in U.S. Dollar-Settled Zero-Coupon Convertible Bonds Due 2027

2026 / 05 / 29

Fangda Advises Genrix Bio on Exclusive Greater China Licensing Collaboration with YaoPharma for BCMA×CD3 Bispecific Antibody

2026 / 05 / 26

Fangda advised VIEWTRIX Technology on its listing as China's first domestic AMOLED display driver chip company on the HKEX

2026 / 05 / 22

Fangda advises Trustar Capital in US$120 Million PIPE investment in Yatsen

2026 / 05 / 14

Fangda Advises on Midea Group’s Successful HKD 17.2 Billion Convertible Bond Offering